Featured Research

from universities, journals, and other organizations

Could discovery lead to end of sunburn pain?

Date:
August 5, 2013
Source:
Duke University
Summary:
The painful, red skin that comes from too much time in the sun is caused by a molecule abundant in the skin's epidermis, a new study shows. Blocking this molecule, called TRPV4, greatly protects against the painful effects of sunburn. The research, which was conducted in mouse models and human skin samples, could yield a way to combat sunburn and possibly several other causes of pain.

The painful, red skin that comes from too much time in the sun is caused by a molecule abundant in the skin's epidermis, a new study shows.
Credit: Robert Kneschke / Fotolia

The painful, red skin that comes from too much time in the sun is caused by a molecule abundant in the skin's epidermis, a new study shows.

Blocking this molecule, called TRPV4, greatly protects against the painful effects of sunburn. The results were published the week of Aug. 5 in the Proceedings of the National Academy of Sciences (PNAS) Early Edition online. The research, which was conducted in mouse models and human skin samples, could yield a way to combat sunburn and possibly several other causes of pain.

"We have uncovered a novel explanation for why sunburn hurts," said Wolfgang Liedtke, M.D., Ph.D., one of the senior authors of the study and associate professor of neurology and neurobiology at Duke University School of Medicine. "If we understand sunburn better, we can understand pain better because what plagues my patients day in and day out is what temporarily affects otherwise healthy people who suffer from sunburn."

The vast majority of sunburns are caused by ultraviolet B or UVB radiation. In moderation, this component of sunlight does the body good, giving a daily dose of vitamin D and perhaps improving mood. But if people get too much, it can damage the DNA in their skin cells and increase their susceptibility to cancer. Sunburns are nature's way of telling people to go inside and avoid further damage.

Liedtke worked together with a multi-institutional team of researchers: Elaine Fuchs, Ph.D., a professor at Rockefeller University and an investigator with the Howard Hughes Medical Institute and skin biologist; and Martin Steinhoff, M.D., Ph.D., professor of dermatology and surgery at the University of California in San Francisco who is known for his studies on sensory function of skin in health and disease. Together, they investigated whether the TRPV4 molecule, which is abundant in skin cells and has been shown to be involved in other pain processes, might play a role in the pain and tissue damage caused by UVB over-exposure. TRPV4 is an ion channel, a gateway in the cell membrane that rapidly lets in positively charged ions such as calcium and sodium.

First, the researchers built a mouse model that was missing TRPV4 only in the cells of the epidermis, the outermost layer of the skin. They took these genetically engineered mice and their normal counterparts and exposed their hind paws -- which most resemble human skin -- to UVB rays. The hind paws of the normal mice became hypersensitive and blistered in response to the UVB exposure, while those of the mutant mice showed little sensitization and tissue injury.

Next, they used cultured mouse skin cells to dissect the activities of TRPV4. Using a device engineered by Nan Marie Jokerst, Ph.D., a professor of electrical and computer engineering at Duke's Pratt School of Engineering, the researchers showed that UVB caused calcium to flow into the skin cells, but only when the TRPV4 ion channel was present.

Further molecular analysis uncovered the entire sequence of events in this pathway, with each event affecting the next: UVB exposure activates TRPV4, which causes the influx of calcium ions, which brings in another molecule called endothelin, which triggers TRPV4 to send more calcium into the cells. Endothelin is known to cause pain in humans and also evokes itching, which could explain the urge sunburned patients feel to scratch their skin.

To test whether these findings in mice and mouse cells have human relevance, the researchers used human skin samples to successfully demonstrate increased activation of TRPV4 and endothelin in human epidermis after UVB exposure.

To see if they could block this novel pain pathway, the researchers used a pharmaceutical compound called GSK205 that selectively inhibits TRPV4. They dissolved this compound into a solution of alcohol and glycerol -- basically, skin disinfectant -- and then applied it to the hind paws of normal mice. The researchers found that the mice treated with the compound were again largely resistant to the pain-inducing and skin-disrupting effects of sunburn. Similarly, when they administered the compound to mouse skin cells in culture, they found that it stopped the UV-triggered influx of calcium ions into the cells.

"The results position TRPV4 as a new target for preventing and treating sunburn, and probably chronic sun damage including skin cancer or skin photo-aging, though more work must be done before TRPV4 inhibitors can become part of the sun defense arsenal, perhaps in new kinds of skin cream, or to treat chronic sun damage," said Steinhoff, co-senior author of the study.

"I think we should be cautious because we want to see what inhibition of TRPV4 will do to other processes going on in the skin," Liedtke added. "Once these concerns will be addressed, we will need to adapt TRPV4 blockers to make them more suitable for topical application. I could imagine it being mixed with traditional sunblock to provide stronger protections against UVB exposure."

The research was supported by grants from the National Institutes of Health (DE018549, DE018549S1,DE018549S2, AR059402, AR31737, AR050452, and P41 EB015897), and the German Research Foundation (DFG; DFG STE 1014/2-2, DFG Ce165/1-1, DFG Ke1672/1-1).


Story Source:

The above story is based on materials provided by Duke University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Carlene Moore, Ferda Cevikbas, H. Amalia Pasolli, Yong Chen, Wei Kong, Cordula Kempkes, Puja Parekh, Suk Hee Lee, Nelly-Ange Kontchou, Iwei Ye, Nan Marie Jokerst, Elaine Fuchs, Martin Steinhoff, and Wolfgang B. Liedtke. UVB radiation generates sunburn pain and affects skin by activating epidermal TRPV4 ion channels and triggering endothelin-1 signaling. Proceedings of the National Academy of Sciences, 2013; DOI: 10.1073/pnas.1312933110

Cite This Page:

Duke University. "Could discovery lead to end of sunburn pain?." ScienceDaily. ScienceDaily, 5 August 2013. <www.sciencedaily.com/releases/2013/08/130805152420.htm>.
Duke University. (2013, August 5). Could discovery lead to end of sunburn pain?. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2013/08/130805152420.htm
Duke University. "Could discovery lead to end of sunburn pain?." ScienceDaily. www.sciencedaily.com/releases/2013/08/130805152420.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins